bluebird bio (BLUE) Granted FDA Accelerated Approval for SKYSONA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Wedbush Stays Sidelined on bluebird bio (BLUE) But Does Sees 'some short-term benefits' for the Company Following Skysona News
September 19, 2022 9:28 AM EDTWedbush analyst David Nierengarten reiterated a Neutral rating and $9.00 price target on bluebird bio (NASDAQ: BLUE).
The analyst comments "While we believe that the approval of SKYSONA is a win for patients suffering from CALD, we see short-term benefits for BLUE. With... More
